Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label don't have a functioning stroke doctor. Show all posts
Showing posts with label don't have a functioning stroke doctor. Show all posts

Tuesday, October 27, 2026

Adjunctive hyperbaric oxygen therapy for post-stroke cognitive impairment: a systematic review and meta-analysis of randomized controlled trials

 

Why do HBOT when there are vastly simpler, cheaper and less risky ways to increase oxygen uptake?

 I can't see any use for HBOT unless it's delivered in the first week and there are vastly easier options for delivering oxygen than that.

Google this for risks: hyperbaric oxygen therapy deaths. 

Here are 43 posts on HBOT for your edification

Well, since this has been around for years why the hell doesn't someone actually do human testing and create protocols on stroke recovery?

Earlier research has this line:The drug, which is cheaply available for just $0.16 a day, works by boosting the number of oxygen molecules released into a cell, which in turn seems to benefit the robustness and longevity of the body’s basic building blocks. (This would seem to be much easier and faster than HBOT. I'm requesting this at my next stroke, my doctor won't know what hit her when I tell her how to treat me.)

If your doctor doesn't know about this s/he IS COMPLETELY FUCKING INCOMPETENT? And not creating protocols is even worse, allowing millions to billions of neurons to die because of lack of oxygen during the neuronal cascade of death!

 What other protocols is your doctor using to significantly improve oxygen delivery immediately post stroke? The first hours and days? NOTHING? Then you DON'T have a functioning stroke doctor, do you?

Maybe these, why isn't your incompetent doctor already delivering these to you?

cerebral blood flow (29 posts to July 2016)

Cerebral blood flow autoregulation (1 post to July 2021)

Cerebral Blood Flow Velocity (1 post to Febraury 2020)

cortical oxygenation (1 post to November 2020)

oxygen delivery (20 posts to January 2020)

oxygen uptake (5 posts to August 2013)

Normobaric oxygen (10 posts to January 2020)

  • brain blood flow (3 posts to April 2019)

  •  Oh, your incompetent doctor doesn't have any and doesn't fucking care about learning better ways to get you recovered! Well, fire them! 

    The latest here:

    Adjunctive hyperbaric oxygen therapy for post-stroke cognitive impairment: a systematic review and meta-analysis of randomized controlled trials


    • Xiaosai Hu

      Xiaosai Hu 1

    • S

      Shurong Zhao 2

    • D

      Dandan Zhang 3

    • X

      Xianguo Meng 1,3*

    • 1. School of Sports Medicine and Rehabilitation, Shandong First Medical University (Shandong Academy of Medical Sciences), Taian, China

    • 2. Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, China

    Abstract


    Objective: 


    To evaluate the effects of adjunctive hyperbaric oxygen therapy (HBOT) on cognitive, neurological, and functional outcomes in patients with post-stroke cognitive impairment (PSCI), and explore potential sources of heterogeneity.


    Methods: 


    Eight databases were searched from inception to July 15, 2026. Randomized controlled trials (RCTs) evaluating adjunctive HBOT in patients with PSCI were included. The primary outcome was the Montreal Cognitive Assessment (MoCA); secondary outcomes included the Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and Barthel Index (BI). Random-effects meta-analyses, prespecified subgroup analyses, and meta-regression were performed. Sensitivity analyses, funnel plots, Egger’s tests, and GRADE assessments were conducted.


    Results: 


    Thirty-five RCTs involving 3,036 participants, all conducted in China, were included. Adjunctive HBOT was associated with higher MoCA scores (MD = 2.90, 95% CI: 2.47–3.33; p < 0.00001; I2 = 84%) and MMSE scores (MD = 2.68, 95% CI: 2.20–3.16; p < 0.00001; I2 = 83%). Improvements were also observed in NIHSS (MD = −2.61, 95% CI: −3.34 to −1.89; p < 0.00001; I2 = 93%), MBI (MD = 6.64, 95% CI: 3.76–9.52; p < 0.00001; I2 = 82%), and BI (MD = 8.77, 95% CI: 4.72–12.82;p < 0.00001; I2 = 82%). No statistically significant subgroup differences were observed for MoCA (p = 0.10) or MMSE (p = 0.43). Higher baseline MoCA scores tended to be associated with smaller treatment effects in meta-regression (β = −0.1411, p = 0.0637; R2 = 15.42%). Substantial heterogeneity remained largely unexplained. Evidence certainty was low for MoCA, MMSE, and MBI and very low for NIHSS and BI.


    Conclusion: 


    Adjunctive HBOT may(NOT GOOD ENOUGH!) provide cognitive and functional benefits in patients with PSCI. However, substantial unexplained heterogeneity, low-to-very-low certainty of evidence, and the exclusively Chinese evidence base warrant cautious interpretation and limit generalizability. Further well-designed RCTs involving diverse populations are needed.


    Systematic review registration:

    https://www.crd.york.ac.uk/PROSPERO/view/CRD420261473579, PROSPERO, CRD420261473579.

    Sunday, October 25, 2026

    Thursday, October 22, 2026

    Psilocybin Tied to Lower Inflammation in Parkinson's Trial

     Is your competent? doctor ready with this to try to prevent Parkinsons after your stroke? Sorry, your doctor doesn't even know of your Parkinson's risk! 

    Haven't you gotten that INCOMPETENT DOCTOR FIRED YET?

    Isn't your doctor already prescribing psilocybin for stroke recovery? Oh NO, you DON'T have a functioning stroke doctor, do you? 

    psilocybin (59 posts to May 2014) 

    Psilocybin Tied to Lower Inflammation in Parkinson's Trial

    Key Takeaways

    • Psilocybin therapy was associated with reduced inflammation in a small trial of Parkinson's patients with mood dysfunction.
    • An inflammatory index remained lower through 30 days, but mitochondrial stress marker reductions were transient.
    • Findings require confirmation in larger randomized controlled trials.

    Markers of systemic inflammation and mitochondrial stress were reduced after psilocybin therapy in Parkinson's disease patients with mood dysfunction, a small nonrandomized trial showed.

    Relative to baseline, an inflammatory index was significantly lower at all follow-up time points after psilocybin was administered, reported Ellen Bradley, MD, of the University of California San Francisco (UCSF), and co-authors.

    The standard mean difference (SMD) was -0.72 (adjusted P=0.003) 1 day after 10 mg of psilocybin, Bradley and colleagues wrote in a JAMA Psychiatry research letter.

    One day after 25 mg of psilocybin, the SMD was -0.60 (adjusted P=0.02), and 30 days after 25 mg, the SMD was -0.62 (adjusted P=.047).

    The results support the researchers' parent trial, which showed an association between psilocybin therapy and reduced depression, anxiety, and motor symptoms in Parkinson's patients.

    "To our knowledge, this is the first report of changes in these types of markers after psychedelic treatment in people with a neurodegenerative disease," Bradley told MedPage Today. "That gives us and other researchers super-interesting biological questions to pursue: What could be producing these changes, are they consistent in larger groups of people, and do they have anything to do with clinical benefits people with Parkinson's might experience with psilocybin?"

    This research comes as part of a series of studies examining the biological effects of psychedelics as potential therapeutics for non-psychiatric conditions, said Albert Garcia-Romeu, PhD, of the Johns Hopkins University School of Medicine in Baltimore, who wasn't involved with the study. It also comes on the heels of work showing that psilocybin appeared to block nerve damage related to chemotherapy in mice, he pointed out.

    Much of the work looking at psilocybin or LSD has focused squarely on mental health conditions like depression, anxiety, or addiction, Garcia-Romeu noted. "However, this study is in patients with a neurological condition -- Parkinson's disease -- and shows evidence that psilocybin may have impacted biological markers of inflammation and mitochondrial stress," he told MedPage Today.

    "These new data suggest biological effects of psychedelics could be driving potential benefits in patients and pave the way for more work to better understand how psilocybin might be a useful therapeutic both in psychiatric and non-psychiatric conditions," he added.

    In their open-label trial, Bradley and colleagues studied 12 people with mild-to-moderate Parkinson's disease ages 40 to 75. Participants received 10-mg and 25-mg doses of oral synthetic psilocybin approximately 2 weeks apart.

    The researchers collected plasma samples from nine participants at four time points: baseline, 1 day after each psilocybin administration, and 30 days after the 25-mg dose.

    The primary outcome to assess systemic inflammation was a proinflammatory index calculated as the mean z score of interleukin (IL)-6, IL-8, tumor necrosis factor alpha, interferon gamma, and high-sensitivity C-reactive protein concentrations. Mitochondrial stress was evaluated with growth differentiation factor 15 (GDF-15) and fibroblast growth factor 21 (FGF-21) measurements.

    Components of the index, including IL-6, were significantly lower 1 day after the 10-mg dose but at no other time points. IL-10 was significantly higher 1 day after the 10-mg dose but not at other times.

    GDF-15 was significantly lower relative to baseline 1 day after each psilocybin administration, but not from baseline 30 days after the 25-mg dose. FGF-21 was higher 1 day after each psilocybin administration, but this finding was not significant.

    This was a small study of psilocybin therapy and results must be interpreted cautiously, noted co-author Aoife O'Donovan, PhD, also of UCSF. "However, the results are highly promising and suggest that more research in this area is warranted," she told MedPage Today. "We are already following this study up with more in-depth analyses of the effects of psilocybin therapy on inflammation and mitochondrial stress in a randomized controlled trial in patients with Parkinson's disease."

    Work from Garcia-Romeu's lab also is studying psilocybin in a trial of people with mild cognitive impairment or early-stage Alzheimer's disease and depression. "To date, we've treated 18 individuals in that study, and enrolled 19 of a targeted 20 patients," he said. "We plan to complete the trial and publish our findings next year."

    Monday, September 28, 2026

    Rhythm of Your Breath Controls Reaction Time

     Your competent? doctor created a breathing protocol years ago based on these books, right? 

    Like:

    'Breath: The New Science of a Lost Art' by James Nestor. Published 2020

    Or;

    'The Oxygen Advantage: Simple, Scientifically Proven Breathing Techniques to Help You Become Healthier, Slimmer, Faster, and Fitter' by Patrick McKeown. Published 2016

    Or should you be doing fast breathing in

    Creation of nitric oxide via Breath of Fire  February 2014 

    And why doesn't your doctor know a damn thing about a breathing protocol?

    Your doctor has had years to know about this. Are you giving them a pass on being incompetent? So, you DON'T have a functioning stroke doctor or hospital, do you?

    Oh NO, INCOMPETENCE REIGNED, nothing doing! What do you do? Call the president and demand some competence in the hospital! That means EXACT 100% RECOVERY PROTOCOLS! 


    Rhythm of Your Breath Controls Reaction Time

    Summary:

    Neuroscientists have discovered that human reaction speed changes across the respiratory cycle, with reaction times averaging 41 milliseconds faster during exhalation than inhalation. The study represents the first continuous measurement of cognitive response speeds across all breathing phases, including breath pauses, revealing that bodily rhythms actively modulate sensory-motor processing.

    Key Facts:

    • The Exhalation Advantage: Participants responded to unexpected visual stimuli an average of 41 milliseconds faster during exhalation than during inhalation, alongside a 21-millisecond advantage during post-breath pauses.
    • Continuous Respiration Tracking: The investigation marks the first experiment to evaluate psychomotor vigilance continuously across all respiratory phases, linking airflow monitoring to millisecond-level motor outputs.
    • Brain Oscillations Synchrony: Researchers suggest the effect is driven by neurophysiological efficiency, building on evidence that fundamental cortical oscillations naturally phase-lock with nasal breathing rhythms.

    Source: Northwestern University

    Whether an Olympic swimmer reacts to the crack of a starting pistol or a highway driver slams on the brakes to avoid an oncoming crash, a fraction of a second often determines victory, defeat, or survival. At 60 mph, a car travels nearly four feet in just 40 milliseconds, a brief window of time where sensory processing speed is paramount.

    Now, a study led by neuroscientists at Northwestern University reveals that this critical response margin is tied directly to the rhythm of our lungs.

    Published in iScience, the research demonstrates that human response times fluctuate reliably across the breathing cycle. When presented with rapid visual prompts, people react significantly faster when exhaling than when inhaling, establishing a functional bridge between autonomic respiratory mechanics and conscious motor readiness.

    “By using a tangible and easy to understand task, we were able to show the relationship between respiration and cognition, which I hope people in a range of fields will find application for,” said lead author Erika M. Yamazaki, Ph.D., a neuroscientist and former member of Northwestern’s Cognitive Neuroscience Laboratory. “Study of the brain and body connection is still a new field of research, which makes the study findings all the more exciting.”

    Mapping Psychomotor Vigilance Across Breaths

    To measure how breathing modulates executive reflexes, the researchers recruited 35 healthy adult participants aged 18 to 33 to perform the Psychomotor Vigilance Task (PVT)—a standard clinical and cognitive measure of sustained attention and reaction latency.

    During the assessment, participants monitored a display screen and pressed the space bar as rapidly as possible whenever a red square turned yellow. Throughout the trials, subjects wore a nasal cannula-style airflow sensor positioned directly under their nostrils to capture real-time respiratory phases with high temporal resolution. Each participant completed testing protocols twice: once before and once after an in-lab sleep period (either a daytime nap or an eight-hour overnight rest).

    By correlating thousands of millisecond-level key presses with simultaneous airflow waveforms, the team identified distinct performance variations:

    • Exhalation vs. Inhalation: Motor responses during active exhalation were an average of 41 milliseconds (approximately 1/25th of a second) faster than responses executed during active inhalation.
    • Breath Pauses: The brief periods of breath retention between inhalation and exhalation also maintained an advantage, clocking in 21 milliseconds faster than inhalation phases.

    “This study documents an important link between respiration and the brain systems for responding to environmental events,” said senior author Ken Paller, Ph.D., the James Padilla Professor of Psychology at Northwestern University. “We don’t yet know exactly how they are linked, but we suspect neurophysiological efficiency, because other studies have shown that various brain oscillations are synchronized with the rhythms of one’s breathing.”

    Respiratory Phase-Locking and Sleep Engineering

    The finding aligns with growing neuroimaging evidence showing that nasal respiration entrains slow-wave neural oscillations across diverse brain networks, including the olfactory bulb, piriform cortex, amygdala, and hippocampus. During inhalation, sensory inputs and emotional memory consolidation undergo specific neural gating; during exhalation and baseline pauses, cortical networks may optimize motor preparation pathways.

    Beyond optimizing athletic reaction starts or high-speed driving reflexes, the researchers emphasize that mapping the respiration-cognition axis has crucial clinical implications for sleep medicine.

    Paller’s laboratory is currently expanding on these findings through an NIH-funded initiative led by Yamazaki that explores the cognitive fallout of obstructive sleep apnea, a widespread, underdiagnosed condition where repeated breathing cessations fragment sleep architecture and erode next-day mental capacity.

    By detailing how respiratory rhythms modulate cortical activity during both waking and resting states, the investigators aim to pioneer noninvasive “sleep engineering” techniques that stabilize breathing patterns and preserve long-term cognitive health.

    Editorial Notes:

    • This article was edited by a Neuroscience News editor.
    • Journal paper reviewed in full.
    • Additional context added by our staff.

    About this Cognitive Neuroscience Research:

    • Media Contact: Stephanie Kulke
    • Source: Northwestern University
    • Image Credit: Image credited to Neuroscience News
    • Original Research is Open Access: iScience (Sept 22, 2026). “Response speed is modulated by respiratory phase.” Authors: Erika M. Yamazaki and Ken A. Paller.
    • DOI: 10.1016/j.isci.2026.117535

    Tuesday, September 8, 2026

    Adjuvant neuroprotective therapies for acute ischemic stroke in the reperfusion era: a comparative narrative review of clinical evidence for edaravone, edaravone-dexborneol, and butylphthalide

     

    You'll have to ask your competent? doctor why the hell edaravone is approved in Japan since 2001 but not the US. If your doctor doesn't know this off the top of the head; you DON'T have a functioning stroke doctor!

    Has your stroke hospital done anything with edaravone in the last decade?

     

    Or Butylphthalide (4 posts to December 2021)

    Or dexborneol (4 posts to February 2024)

    The latest here:

    Adjuvant neuroprotective therapies for acute ischemic stroke in the reperfusion era: a comparative narrative review of clinical evidence for edaravone, edaravone-dexborneol, and butylphthalide


    • 1. Department of Neurology, First People's Hospital of Jiande City, Hangzhou, Zhejiang, China

    • 2. Department of Scientific Research, First People's Hospital of Jiande City, Hangzhou, Zhejiang, China

    Abstract

    Reperfusion therapies, including intravenous thrombolysis and endovascular treatment (EVT), are central to acute ischemic stroke (AIS) management; however, ischemia–reperfusion injury may limit recovery despite successful recanalization. This structured narrative review compares the clinical evidence, safety signals, and mechanistic literature for edaravone, butylphthalide (NBP), and the fixed-dose combination edaravone-dexborneol (EDB) as adjunctive neuroprotective approaches. The evidence base is heterogeneous with respect to population, background reperfusion treatment, outcome timing, and geographical setting. In TASTE-2, EDB administered before EVT was associated with a modest increase in 90-day functional independence versus placebo (55.0% vs. 49.6%, p = 0.05), without an apparent safety signal; bridging alteplase was permitted in a subset of participants. In the BAST trial, NBP improved the prespecified 90-day functional outcome versus placebo among patients receiving intravenous thrombolysis and/or EVT (56.7% vs. 44.0%). Observational studies and meta-analyses provide supportive but non-confirmatory evidence for edaravone. Network meta-analyses generate relative rankings at individual endpoints, but indirect comparisons and differing outcome networks preclude definitive between-agent selection. Mechanistic studies indicate overlapping antioxidant, anti-inflammatory, mitochondrial, and neurovascular effects rather than exclusive pathway regulation. Biomarker and imaging approaches, including exploratory GFAP and UCH-L1 measurements, are promising research tools but are not yet validated for treatment selection in AIS. Accordingly, these agents should be regarded as candidates for further evidence-informed adjunctive use; future trials are needed to define reproducible patient-selection and treatment-timing strategies.

    Tuesday, September 1, 2026

    New research explores the earliest stages of coronary plaque inflammation

     Didn't your competent? doctor show you this video on how plaque forms and why cholesterol is not the problem?; INFLAMMATION IS! NO! So you DON'T have a functioning stroke doctor, do you? Why hasn't s/he been fired yet?

    4 min. 36 seconds of explanation. This is what happened to my right carotid artery. My doctor should have explained this but no, he didn't say anything.

    The accent is a bit hard to understand and needs to be  rerecorded to a laypersons understanding. 

    New research explores the earliest stages of coronary plaque inflammation

    A Cedars-Sinai Health Sciences University-led study has identified molecular changes that appear to trigger atherosclerosis years before inflammation, sharing their findings in European Heart Journal.[1]

    The group believes this could a key discovery in the development of next-generation early prevention therapies. 

    The study's authors found previously unrecognized molecular pathways and a possible master regulator protein called MLXIPL that could become future targets for clinicians working to stop plaque from ever developing.

    “We analyzed proteins and gene activity in coronary artery tissue from young adults who died of trauma and had no known coronary artery disease, and we found that more than half already had preclinical atherosclerosis,” first author Sarah Parker, PhD, an associate professor of cardiology and biomedical sciences and co-director of the proteomics and metabolomics core at Cedars-Sinai Health Sciences University, said in a statement. “This suggests that changes in cellular metabolism and communication begin before the inflammation long considered a hallmark of the disease.”

    Parker said this research provides a direct picture of what is happening inside the artery wall and may explain why some people are more vulnerable to heart disease than others.There have been studies showing very early atheroma lesions appearing in the first decade of life. Even with that in mind, however, questions have remained. 

    "What we haven’t understood is what causes those early changes to progress into dangerous plaques that lead to heart attacks," Parker explained. "In studying coronary artery tissue before people ever developed symptoms, we were able to capture some of the earliest molecular changes that appear to set the disease in motion."

    She said a big surprise from this research is that there are cellular metabolism and communication changes before the development of the classic inflammatory signals usually associated with atherosclerosis. There has been a lot of research focused on addressing inflammation to prevent heart disease, but this takes things even further and may offer help identify new preventive therapies.

    "What our study suggests is that important molecular changes begin much earlier," Parker said. "If we want to prevent plaque from forming, we need to understand those earliest changes—not just what happens after inflammation has already taken hold."

    She explained that proteins can tell researchers how the body’s cells are responding to risk factors like cholesterol, blood pressure or smoking. The differences in protiens found in people's cells can help explain why people with identical cholesterol levels will result in one never having coronary disease, while the other develops plaques.


    Wednesday, August 26, 2026

    Psilocybin may make the brain more organized than scientists expected

    Isn't your doctor already the competent one already prescribing psilocybin for stroke recovery? Oh NO, you DON'T have a functioning stroke doctor, do you? 

    psilocybin (58 posts to May 2014) 

     Psilocybin may make the brain more organized than scientists expected

    Researchers tracked psychedelic-naive adults across four very different brain-scanning environments to reveal how setting, brain dynamics and subjective experience interact during a psilocybin session.

    Study: Psychedelics align brain activity with context. Image Credit: Smit / Shutterstock

    A recent study published in the journal Nature investigated how psilocybin alters brain connectivity and organization across different environmental contexts.

    Neural and Contextual Mechanisms of Psychedelic Action

    Psychedelics are a diverse class of psychoactive substances that profoundly alter perception, mood, and cognition. They can induce striking changes in consciousness and sensory experience, including vivid visual or auditory hallucinations, a distorted sense of time, and deeply introspective or spiritual states. Compounds such as psilocybin and mescaline have a long history of use in both ceremonial and therapeutic settings. Recent research highlights their potential for lasting therapeutic effects, including reductions in depression, anxiety, and addiction, as well as enhanced social connectedness and well-being. At the neural level, psychedelics disrupt the brain’s integration of sensory input with internal models of reality. Preclinical studies indicate that psilocybin can promote structural and functional plasticity, while human imaging studies show altered communication between large-scale brain networks, leading to intensified immersion and altered self-perception. These effects are linked to more entropic, desynchronized brain dynamics, particularly within the default mode network (DMN), which is a key hub for integrating information across the brain. Psilocybin can relax connectivity patterns that normally constrain brain networks, allowing novel interactions between sensory and associative regions that may be relevant to its therapeutic effects. However, the precise mechanisms linking these neural changes to meaningful subjective experiences remain unclear.

    Psychedelic outcomes are highly context-dependent, shaped by mindset and environment. However, research in this field is limited by small sample sizes, narrow imaging approaches, and studies conducted in single, artificial contexts, all of which limit generalizability. Additionally, structured tasks during brain scans may fail to capture the richness of natural psychedelic experiences. Addressing these limitations by employing larger samples, multimodal imaging, and more ecologically valid context manipulations remains a central challenge for the field.

    Researchers Examined How Psychedelics Affect Brain Activity and Subjective Experience

    In the open-label PsiConnect study, researchers conducted two imaging sessions: one at baseline and one after a fixed 19 mg dose of psilocybin. Each session included magnetic resonance imaging (MRI) and electroencephalography (EEG) scans across four conditions: resting state, guided meditation, music listening, and movie watching. Functional magnetic resonance imaging (fMRI) began roughly 80 minutes after dosing, following a fixed sequence to ensure safety for participants new to psychedelics. EEG sessions started after setup, beginning with the movie condition. All four conditions: resting state (eyes closed), guided meditation (audio prompts), music listening (curated playlist), and movie watching (silent clouds) were repeated at both time points.

    Sixty-five participants were recruited (aged 18–55; 30 female, 35 male), stratified by age and self-reported gender, and then assigned to either an 8-week mindfulness-based intervention or a control group using a non-randomized, balanced procedure without blinding. No significant group differences emerged in the connectivity or acute subjective-effect measures examined, so data were pooled for analysis. Sample size was limited by recruitment and imaging capacity.

    The fixed 19 mg dose was selected to be tolerable during imaging while producing substantial subjective effects. Behavioral and subjective measures were collected at multiple time points, with follow-up assessments extending to one year post-psilocybin.

    Sixty-five healthy adults with no prior psychedelic experience producing subjective effects underwent extensive screening; three reported nominal or remote serotonergic psychedelic exposures with minimal or no recalled effects. Psilocybin administration was generally well tolerated, although three participants reported transient headaches during the night. Separately, three participants received a brief telephone follow-up from a clinical psychologist and required no further support.

    Context-Driven Neural Patterns Under Psilocybin

    Psilocybin reorganized brain connectivity, reducing global functional connectivity (GFC) in sensory regions and increasing it in associative regions during eyes-closed conditions. Under eyes-open conditions, GFC increased in both sensory and associative areas. These robust effects are consistent with prior research, despite individual variability.

    Spatial patterns of brain signal variability shifted with context. Eyes-open movie viewing increased variability in several cortical regions, while eyes-closed conditions, especially with music, decreased variability in early visual areas. Increases were partially lateralized to the right hemisphere during eyes-closed conditions, and occipital decreases mirrored GFC patterns, a redistribution consistent with increased brain-signal entropy under psilocybin.

    GFC values in the eyes-open and eyes-closed states converged under psilocybin, particularly within the visual network, with the gap shrinking by 85%. Functional modularity decreased across all conditions, largely due to reduced within-network connectivity, an effect that previous clinical studies have associated with longer-term symptom improvement. Machine learning produced low-dimensional neural representations that reliably differentiated conditions and mapped brain patterns to subjective experience.

    Greater subjective-effect intensity was associated with increasingly distinct, context-specific neural organization. Stronger subjective effects produced more distinct, condition-specific neural patterns, with brain organization scaling to effect intensity.

    Context-dependent neural organization was robust across dimensionality reduction methods. Classification accuracy for brain patterns peaked in those with strong self- or boundary-dissolving effects and was associated with positive next-day mindset changes. This alignment was not captured by average network segregation measures.

    In a network perturbation analysis, context alignment depended most strongly on altered dynamics in both the default mode network (DMN) and the visual network. TAVRNN analysis confirmed that psilocybin produced dynamic, low-dimensional patterns reflecting evolving brain connectivity.

    TAVRNN, a machine-learning model that tracks changes in brain connectivity over time, showed more cohesive organization both within individual networks and across the brain. These patterns scaled with subjective-effect intensity and were broadly preserved across contexts.

    Psychedelic-naive participants reported profoundly meaningful effects, often ranking psilocybin as a top life event. Self- and boundary-dissolving experiences were common, with group-level increases in death acceptance, personal meaning, and nature relatedness measured after one month.

    Anterior hippocampus–DMN effective connectivity shifted most during movie viewing, indicating that external context strongly reorganizes network interactions under psilocybin. Brief mindfulness training produced no detectable group-level differences in the acute subjective effects or connectivity measures examined, but music strongly enhanced emotional engagement and was associated with the greatest global brain organization in the TAVRNN analysis.

    EEG results showed that psilocybin’s effects on brain power and complexity depend on sensory context, altering neural oscillations and signal diversity. Findings support context alignment as a cross-modal brain property.

    Machine learning linked self- and boundary-dissolution to more integrated, context-aligned brain dynamics, while the authors described the corresponding subjective state as 'embeddedness': the experience of being continuous with, rather than separate from, the environment. The authors proposed embeddedness as a construct that links acute experience to subsequent psychological change, thereby supporting the temporary dissolution of internal–external boundaries.

    Across measures and contexts, psilocybin reorganizes brain connectivity, redistributing sensory and associative integration in a context-dependent manner and blurring the boundary between internal and external processing. These effects are strongest with positive experiences, and a measurable neural signature is identified, associated with acute subjective experience and subsequent psychological change.

    Conclusions

    Psilocybin induces a dynamic reorganization of brain connectivity, characterized by context-dependent redistribution of integration across associative and sensory networks, effectively blurring the distinction between internal and external processing. This flexible neural state is most pronounced during positive, self-dissolving experiences and is reflected in both subjective reports and context-driven brain activity patterns identified by machine learning.

    These findings identify a measurable neural signature linking context-sensitive brain organization with acute subjective experience and next-day mindset change, and suggest that context and subjective experience may help shape the therapeutic potential of psilocybin, although therapeutic efficacy was not tested in this healthy cohort.

    Journal reference:

    Tuesday, August 25, 2026

    What is Glutathione? What are the Benefits of Glutathione?

     Your competent? doctor has this covered already, right? Oh NO, you DON'T have a functioning stroke doctor, do you?

    What is Glutathione? What are the Benefits of Glutathione?